1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Isocitrate Dehydrogenase (IDH)

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producingalpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate(a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as themitochondrion and peroxisome.

Isocitrate Dehydrogenase (IDH) 相关产品 (16):

Cat. No. Product Name Effect Purity
  • HY-18767
    Ivosidenib Inhibitor 99.24%
    Ivosidenib (AG-120) 是异柠檬酸脱氢酶 1 的突变体酶 (mIDH1 enzyme) 的口服活性抑制剂,它使 d-2- hydroxyglutatrate (2-HG) 在体内降低。Ivosidenib 具有良好的的安全性和临床活性,具有 AML 研究的潜力。
  • HY-18690
    Enasidenib Inhibitor 99.95%
    Enasidenib是可口服,可逆,选择性的 IDH2 突变酶抑制剂,抑制IDH2R140Q 和 IDH2R172KIC50 分别为100 和 400 nM。
  • HY-104042
    Vorasidenib Inhibitor 99.87%
    Vorasidenib (AG-881) 是一种可口服的、脑渗透的第二代突变体异柠檬酸脱氢酶 1 和 2 (mIDH1/2) 双重抑制剂。Vorasidenib (AG-881) 以纳摩尔抑制 D-2-HG,对 IDH1 R132C、IDH1 R132G、IDH1 R132H、IDH1 R132S 的 IC50 值为 0.04~22 nM,对 IDH2 R140Q 值为 7~14 nM,对 IDH2 R172K 的值为 130 nM。
  • HY-15734
    AGI-6780 Inhibitor 98.87%
    AGI-6780 有效且选择性抑制肿瘤相关突变体 IDH2R140QIC50 为 23±1.7 nM。AGI-6780 对 IDH2WT 的作用效果微弱,IC50 为 190±8.1 nM。
  • HY-100020
    BAY-1436032 Inhibitor 98.94%
    BAY-1436032 是一种新型的泛突变异柠檬酸脱氢酶 1 (IDH1) 抑制剂。
  • HY-18082
    AGI-5198 Inhibitor 99.99%
    AGI-5198 (IDH-C35) 是有效和选择性的突变体 IDH1R132H 抑制剂,IC50 为 0.07 μM。
  • HY-19540
    GSK864 Inhibitor 99.68%
    GSK864是异柠檬酸脱氢酶1 (IDH1) 突变体抑制剂; 抑制IDH1突变体R132C,R132H和R132G的IC50值分别为8.8,15.2和16.6 nM。
  • HY-114226
    Olutasidenib Inhibitor 98.35%
    Olutasidenib (FT-2102) 是一种,具有口服活性的、能透过血脑屏障的、突变型异柠檬酸脱氢酶 (IDH)1 的选择性有效抑制剂,对IDH1- R132H 和 IDH1- R132C的 IC50 值分别为 21.2 nM 和 114 nM。可用于研究急性髓性白血病或骨髓增生异常综合征。
  • HY-18690A
    Enasidenib mesylate Inhibitor 99.25%
    Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。
  • HY-18767A
    (R,S)-Ivosidenib Inhibitor 98.61%
    (R,S)-Ivosidenib ((R,S)-AG-120) 是 Ivosidenib (AG-120) 的对映体,活性较低。
  • HY-104036
    IDH-305 Inhibitor 98.61%
    IDH-305 是一种口服性、突变选择性和脑渗透性的 IDH1 抑制剂,靶向 IDH1 (R132) 突变。IDH-305 对突变体 IDH1 亚型的选择性比野生型高 200 倍 (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT))。
  • HY-129545
    DS-1001b Inhibitor 98.90%
    DS-1001b 是一种有效的 IDH-1 (异柠檬酸脱氢酶-1) 突变体抑制剂,详细信息请参考专利文献 WO2016052697A1 中的例 168。
  • HY-12475
    Mutant IDH1-IN-1 Inhibitor 99.60%
    Mutant IDH1-IN-1是 IDH1 突变体的选择性抑制剂,对突变体IDH1 R132C/R132C,IDH1 R132H/R132H,IDH1 R132H/WT和野生型IDH1的 IC50 值分别为4, 42, 80 和 143 nM。
  • HY-13972
    Mutant IDH1 inhibitor Inhibitor 98.69%
    Mutant IDH1 inhibitor 是一个有效的突变型 IDH1 R132H 的抑制剂,IC50 值小于 72 nM。
  • HY-18717
    Mutant IDH1-IN-2 Inhibitor >98.0%
    Mutant IDH1-IN-2是一种突变型异柠檬酸脱氢酶 (IDH) 蛋白抑制剂, 在LS-MS生物化学检测中IC50值为<22 nM, 荧光生物化学检测中IC50值为16.6 nM。
  • HY-114459
    Mutant IDH1-IN-4 Inhibitor >99.0%
    Mutant IDH1-IN-4 (compound 434) 是一种突变型异柠檬酸脱氢酶 1 (IDH 1) 的抑制剂,其对R132H、HT1080 和U87R132H细胞中的突变型IDH 1 的IC50 值 ≤ 0.5 μM。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.